$147 Million

COMPASS Pathways

Initial Public Offering

Lead Left Bookrunner, September 2020

COMPASS Pathways plc is a biopharma company pioneering the development of psilocybin therapy, with an initial focus on treatment-resistant depression (TRD), a subset of major depressive disorder (MDD), comprising 100 million patients who are not helped after two or more antidepressant treatments. The Company has developed a proprietary, synthesized crystalline formulation of psilocybin, COMP360. The Company’s psilocybin therapy comprises administration of COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications.

More Like This

Oct 2020
$219 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Oct 2020
$104 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Oct 2020
$232 Million

Initial Public Offering

Bookrunner

View Details